These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20634077)

  • 1. A simple procedure for the derivation of electron density based surfaces of drug-receptor complexes from a combination of X-ray data and theoretical calculations.
    Mebs S; Lüth A; Luger P
    Bioorg Med Chem; 2010 Aug; 18(16):5965-74. PubMed ID: 20634077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
    Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
    Li DD; Lv PC; Zhang H; Zhang HJ; Hou YP; Liu K; Ye YH; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(16):5012-22. PubMed ID: 21763148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
    Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
    PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
    Mathew MP; Tan E; Saeui CT; Bovonratwet P; Liu L; Bhattacharya R; Yarema KJ
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1223-7. PubMed ID: 25690786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
    Park JH; Liu Y; Lemmon MA; Radhakrishnan R
    Biochem J; 2012 Dec; 448(3):417-23. PubMed ID: 23101586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Han X; Hu L; Li Z; Geng Z; Wang Z; Zeng C; Xiao X
    Anticancer Agents Med Chem; 2015; 15(2):267-73. PubMed ID: 25175686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of drug efficacy within the EGF receptor revealed by microsecond molecular dynamics simulation.
    Wan S; Wright DW; Coveney PV
    Mol Cancer Ther; 2012 Nov; 11(11):2394-400. PubMed ID: 22863610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
    Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
    Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
    Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design.
    Nandi S; Bagchi MC
    Mol Divers; 2010 Feb; 14(1):27-38. PubMed ID: 19330460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity.
    Alsalme A; Pooventhiran T; Al-Zaqri N; Rao DJ; Rao SS; Thomas R
    J Mol Model; 2020 Nov; 26(12):341. PubMed ID: 33200284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach.
    Zhou J; Fang L; Yang Z; Xu S; Lv M; Sun Z; Chen J; Wang D; Gao J; Xiao S
    FASEB J; 2019 Dec; 33(12):14575-14587. PubMed ID: 31690127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying the Conformation of a Receptor Tyrosine Kinase in Solution by Inhibitor-Based Spin Labeling.
    Yin DM; Hannam JS; Schmitz A; Schiemann O; Hagelueken G; Famulok M
    Angew Chem Int Ed Engl; 2017 Jul; 56(29):8417-8421. PubMed ID: 28628261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.